Teamwork Financial Advisors LLC Cuts Stake in Amgen Inc. $AMGN

Teamwork Financial Advisors LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 89.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 1,000 shares of the medical research company’s stock after selling 8,835 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Amgen were worth $362,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in AMGN. Norges Bank purchased a new position in Amgen in the 4th quarter worth $2,164,162,000. Capital World Investors boosted its position in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after buying an additional 4,302,237 shares during the period. State Street Corp boosted its position in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after buying an additional 1,287,310 shares during the period. Geode Capital Management LLC grew its stake in shares of Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after buying an additional 1,035,779 shares during the last quarter. Finally, Amundi increased its holdings in shares of Amgen by 41.1% in the fourth quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after buying an additional 988,856 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is owned by insiders.

Amgen Stock Up 1.5%

Shares of NASDAQ:AMGN opened at $410.95 on Friday. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $418.40. The company has a market cap of $221.79 billion, a PE ratio of 25.54, a P/E/G ratio of 3.77 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.01. The stock’s 50-day moving average is $362.77 and its 200 day moving average is $356.24.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the prior year, the company posted $6.02 EPS. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.73 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio is currently 62.65%.

Analyst Upgrades and Downgrades

AMGN has been the subject of several analyst reports. Oppenheimer increased their target price on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday. UBS Group boosted their price objective on Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday. TD Cowen increased their price objective on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Wells Fargo & Company lifted their target price on shares of Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $370.07.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.